Risk of myelodysplastic syndrome and acute myeloid leukemia following autologous transplantation for lymphoma according to pretransplantation radiotherapy and radiation dose to active bone marrow, without adjustment for transplantation-related factors
| Risk Factors . | Cases/controls . | RR . | 95% CI . | P . |
|---|---|---|---|---|
| Model 1:3-150 pretransplantation radiotherapy | ||||
| No | 32/102 | 1.0 | — | — |
| Yes | 24/66 | 1.4 | 0.68-2.89 | .37 |
| Model 2:3-151 radiation dose to active bone marrow | ||||
| No | 32/102 | 1.0 | — | — |
| Medium3-152 | 12/29 | 1.5 | 0.63-3.71 | .35 |
| High3-153 | 12/37 | 1.1 | 0.46-2.75 | .79 |
| Ptrend.75 |
| Risk Factors . | Cases/controls . | RR . | 95% CI . | P . |
|---|---|---|---|---|
| Model 1:3-150 pretransplantation radiotherapy | ||||
| No | 32/102 | 1.0 | — | — |
| Yes | 24/66 | 1.4 | 0.68-2.89 | .37 |
| Model 2:3-151 radiation dose to active bone marrow | ||||
| No | 32/102 | 1.0 | — | — |
| Medium3-152 | 12/29 | 1.5 | 0.63-3.71 | .35 |
| High3-153 | 12/37 | 1.1 | 0.46-2.75 | .79 |
| Ptrend.75 |
RR indicates relative risk; CI, confidence interval; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; and —, reference group.
Reference group consists of patients with no or low-dose radiotherapy (eg, limb, head, neck or other minor field). RRs are adjusted for therapies with MOPP (1 variable), chlorambucil (1 variable), and other alkylating agents (1 variable).
RRs are adjusted for cumulative dose of mechlorethamine (2 variables), duration of chlorambucil (2 variables), and therapy with other alkylating agents (1 variable).
Includes low to moderate irradiation doses to mantle/mediastinal fields (mean, 2980 cGy) or subdiaphragmatic fields (mean, 3140 cGy; eg, inverted Y, para-aortic, and pelvic).
Includes high-dose irradiation to mantle/mediastinal fields (mean, 3900 cGy), or subdiaphragmatic fields (mean, 4200 cGy), or sub- or total lymphoid irradiation.